AAO '26: BRUNELLO and LUGANO

Could a Wnt pathway agonist match anti-VEGF therapy for DME, and what should we make of a phase 3 trial that hit its anatomic goals but missed its primary visual endpoint? Don D’Amico, MD, reviews one-year results from the phase 2b/3 BRUNELLO study of remigromig (Restoret, Merck/EyeBio), a Wnt pathway agonist, for diabetic macular edema. And Carl Regillo, MD, discusses the phase 3 LUGANO study of EYP-1901 (vorolanib, EyePoint Pharmaceuticals) for wet AMD, which missed its primary endpoint despite reducing treatment burden by 42%.